Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone Marrow

Inclusion Criteria: * Patients, with primary breast cancer who had undergone complete primary tumor resection and axillary lymph node dissection * Evidence of minimal residual disease (disseminated tumor cells in bone marrow) * Patients had to receive one of the following adjuvant therapy categories: chemotherapy ± hormonal therapy or hormonal therapy alone Exclusion Criteria: * Inflammatory, metastatic or recurrent breast cancer or a history of breast cancer prior to the currently diagnosed case * Neo-adjuvant chemotherapy, neo-adjuvant hormonal therapy, or neo-adjuvant radiotherapy * Prior stem cell rescue/bone marrow transplant * History of other cancers aside from non-melanomatous skin cancer or carcinoma in situ of the uterine cervix Additional protocol-defined inclusion / exclusion criteria may apply